Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Retained Earnings (2016 - 2026)

Iradimed has reported Retained Earnings over the past 14 years, most recently at $67.5 million for Q1 2026.

  • Quarterly Retained Earnings rose 13.78% to $67.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $67.5 million through Mar 2026, up 13.78% year-over-year, with the annual reading at $64.2 million for FY2025, 13.1% up from the prior year.
  • Retained Earnings was $67.5 million for Q1 2026 at Iradimed, up from $64.2 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $67.5 million in Q1 2026 and troughed at $6127.0 in Q1 2022.
  • The 5-year median for Retained Earnings is $47.4 million (2024), against an average of $48.7 million.
  • Year-over-year, Retained Earnings tumbled 80.98% in 2022 and then soared 611087.2% in 2023.
  • A 5-year view of Retained Earnings shows it stood at $47.3 million in 2022, then dropped by 8.48% to $43.3 million in 2023, then skyrocketed by 31.28% to $56.8 million in 2024, then rose by 13.1% to $64.2 million in 2025, then rose by 5.08% to $67.5 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Retained Earnings are $67.5 million (Q1 2026), $64.2 million (Q4 2025), and $66.3 million (Q3 2025).